Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Common Equity (2019 - 2025)

Historic Common Equity for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $835.1 million.

  • Harmony Biosciences Holdings' Common Equity rose 3993.25% to $835.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $835.1 million, marking a year-over-year increase of 3993.25%. This contributed to the annual value of $659.2 million for FY2024, which is 4114.91% up from last year.
  • Harmony Biosciences Holdings' Common Equity amounted to $835.1 million in Q3 2025, which was up 3993.25% from $773.1 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Common Equity's 5-year high stood at $835.1 million during Q3 2025, with a 5-year trough of $107.9 million in Q1 2021.
  • Its 5-year average for Common Equity is $436.6 million, with a median of $467.0 million in 2023.
  • In the last 5 years, Harmony Biosciences Holdings' Common Equity soared by 12621.27% in 2022 and then soared by 1100.87% in 2024.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Common Equity stood at $186.5 million in 2021, then surged by 115.99% to $402.8 million in 2022, then grew by 15.93% to $467.0 million in 2023, then soared by 41.15% to $659.2 million in 2024, then rose by 26.7% to $835.1 million in 2025.
  • Its Common Equity stands at $835.1 million for Q3 2025, versus $773.1 million for Q2 2025 and $720.5 million for Q1 2025.